Access clinical evidence, dosing guidance and key publications relating to the use of Teysuno® (tegafur/gimeracil/oteracil), also know as S-1, in metastatic colorectal cancer (mCRC).
Prescribing information
Full prescribing information for Teysuno® (tegafur/gimeracil/oteracil) for use in the United Kingdom.Introduction video to Teysuno
Educational video on fluoropyrimidine-related HFS and CVT and the role of Teysuno® in mCRC – Prof. C. Punt, medical oncologist, the Netherlands.Core slide deck
Clinical evidence supporting the use of Teysuno® in metastatic colorectal cancer (mCRC).Dosing card
Practical dosing and switching guidance for the use of Teysuno® in metastatic colorectal cancer (mCRC).Pivotal publication
Access the key publications supporting the use of Teysuno® in metastatic colorectal cancer (mCRC).SmPC
View the full Summary of Product Characteristics for Teysuno® (tegafur/gimeracil/oteracil).Stay connected
Sign up to stay informed on Teysuno's latest scientific information.
Adverse events should be reported
Reporting forms and information can be found at
yellowcard.mhra.gov.uk
or search for MHRA Yellow Card in the Google Play or Apple App Store.
Adverse events should also be reported to Nordic Pharma at
medinfo.uk@nordicpharma.com